[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600636":3},{"organization":4,"outcomesModule":7,"designInfo":71,"detailedDescription":78,"studyPopulation":70,"armGroups":79,"interventions":86,"overallOfficials":92,"centralContacts":97,"locations":107,"responsibleParty":156,"collaborators":158,"id":161,"slug":70,"hasResults":162,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":70,"eligibilityCriteria":166,"healthyVolunteers":162,"sex":167,"minAge":168,"maxAge":70,"enrollmentInfo":169,"targetDuration":70,"studyType":172,"phases":173,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":126,"whyStopped":70,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":189},{"fullName":5,"class":6},"Nanjing Legend Biotech Co.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":36,"otherOutcomes":70},[9,13,17,21,25,28,32],{"measure":10,"description":11,"timeFrame":12},"Dose-limiting toxicity (DLT) rate.","DLT is classified according to the NCI-CTCAE V5.0 toxicity evaluation criteria and ASTCT consensus classification within 30 days after dose infusion (D1-D30), which is considered by the investigator or collaborator to be reasonably related to LCAR-F33S cell therapy.","From LCAR-F33S cell infusion (Day 1) until the 30th day of follow-up period, assessed up to 30 days",{"measure":14,"description":15,"timeFrame":16},"Incidence, severity, and type of treatment-emergent adverse events (TEAEs)","An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.","From the date of signing ICF to the date 2 years after LCAR-F33S cell infusion",{"measure":18,"description":19,"timeFrame":20},"To determine the recommended dose for phase II clinical trials (RP2D)","RP2D was established through accelerated titration design (ATD) and Bayesian Optimal Interval (BOIN) design.","through the last subject of DLT exploration completion, about 2years.",{"measure":22,"description":23,"timeFrame":24},"Maximum concentration (Cmax)","The maximum observed concentration of CAR positive T cells or transgene CAR copy number in peripheral blood.","From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion, assessed about 2 years",{"measure":26,"description":27,"timeFrame":24},"Time to Cmax","The time it takes to reach the maximum concentration of CAR positive T cells or transgene CAR copy number in peripheral blood.",{"measure":29,"description":30,"timeFrame":31},"Time to the last observed concentration","The time it takes to reach the last observed concentration of CAR positive T cells or transgene CAR copy number in peripheral blood.","From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years",{"measure":33,"description":34,"timeFrame":35},"Area Under the Curve (AUC) of the concentration","The exposure of CAR positive T cells or transgene CAR copy number in peripheral blood experienced by the subject in a certain time interval.","From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion, assessed about 2 years.",[37,40,43,46,49,53,56,60,63,66],{"measure":38,"description":39,"timeFrame":24},"Objective Response Rate (ORR)","According to International Myeloma Working Group (IMWG) efficacy criteria. ORR is defined as the proportion of patients with PR or better response after infusion of LCAR-F33S cells.",{"measure":41,"description":42,"timeFrame":31},"Very Good Partial Response Rate（VGPR）","Proportion of subjects achieving VGPR according to IMWG criteria.",{"measure":44,"description":45,"timeFrame":31},"Complete response(CR)","Proportion of subjects achieving CR according to IMWG criteria.",{"measure":47,"description":48,"timeFrame":31},"Stringent complete response(sCR)","Proportion of subjects achieving sCR according to IMWG criteria.",{"measure":50,"description":51,"timeFrame":52},"Minimal residual disease (MRD) negative rate","Proportion of subjects achieving minimal residual disease (MRD) negative rate according to IMWG criteria.","From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression, assessed about 2 years",{"measure":54,"description":55,"timeFrame":24},"Time-to-response(TTR)","According to International Myeloma Working Group (IMWG) efficacy criteria. TTR is defined as the interval from the date of the first infusion of the LCAR-F33S cells to the date of the first efficacy assessment for which the subject met all criteria for PR or better. Analyses were performed only in responders.",{"measure":57,"description":58,"timeFrame":59},"Duration of response(DOR)","According to International Myeloma Working Group (IMWG) efficacy criteria. DOR is defined as the time from the first documented response (PR or better response) to the first documented evidence of disease progression (as defined according to IMWG criteria) or death from any cause.","From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years.",{"measure":61,"description":62,"timeFrame":35},"Progression-free survival(PFS)","According to International Myeloma Working Group (IMWG) efficacy criteria. PFS is defined as the interval from the date of the first infusion of the LCAR-F33S cells to the first documentation of disease progression (according to IMWG criteria) or death from any cause, whichever occurred first.",{"measure":64,"description":65,"timeFrame":35},"Overall survival(OS)","According to International Myeloma Working Group (IMWG) efficacy criteria. Overall survival (OS) is defined as the interval from the date of the first infusion of LCAR-F33S cells to death.",{"measure":67,"description":68,"timeFrame":69},"Occurrence rate of antidrug antibody","Occurrence rate of LCAR-F33S cells preparation ADA.","From LCAR-F33S cells infusion until the date of first documented progression or study completion, assessed about 2 years.",null,{"allocation":72,"interventionModel":73,"interventionModelDescription":74,"primaryPurpose":75,"observationalModel":70,"timePerspective":70,"maskingInfo":76},"NA","SINGLE_GROUP","Single Group Assignment ，LCAR-F33S cells intravenous infusion Pretreatment of cyclophosphamide and fludarabine.","TREATMENT",{"masking":77,"maskingDescription":70,"whoMasked":70},"NONE","This study is a prospective, single-arm, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-F33S in patients with relapsed\u002Frefractory multiple myeloma. All subjects who meet the eligibility criteria will receive intravenous injection of LCAR-F33S cell injection. The study will include the following sequential phases: screening, apheresis, pre-treatment (lymphodepleting chemotherapy), treatment, and follow-up.",[80],{"label":81,"type":82,"description":83,"interventionNames":84},"LCAR-F33S","EXPERIMENTAL","Each subject will be given a single-dose LCAR- F33S cells infusion at each dose level.",[85],"Biological: LCAR- F33S cells intravenous infusion",[87],{"type":88,"name":89,"description":90,"armGroupLabels":91,"otherNames":70},"BIOLOGICAL","LCAR- F33S cells intravenous infusion","Prior to infusion of the LCAR- F33S cell, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.",[81],[93],{"name":94,"affiliation":95,"role":96},"Lugui Qiu, MD","Institute of Hematology & Blood Diseases Hospital, China","PRINCIPAL_INVESTIGATOR",[98,103],{"name":99,"role":100,"phone":101,"phoneExt":70,"email":102},"Tingting Wang","CONTACT","+86 18618260033","tingting.wang@legendbiotech.cn",{"name":104,"role":100,"phone":105,"phoneExt":70,"email":106},"Jianling Yao","+86 18610091176","jianling.yao@legendbiotech.cn",[108,124,136,144],{"facility":109,"status":110,"city":111,"state":70,"zip":70,"country":112,"countryCode":113,"cosmosGeoPoint":114,"geoPoint":119,"contacts":120},"Beijing Boren Hospital","NOT_YET_RECRUITING","Beijing","China","CN",{"type":115,"coordinates":116},"Point",[117,118],116.39723,39.9075,{"lat":118,"lon":117},[121],{"name":122,"role":100,"phone":70,"phoneExt":70,"email":123},"Yajing Zhang, MD","23975701@qq.com",{"facility":125,"status":126,"city":127,"state":70,"zip":70,"country":112,"countryCode":113,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Institute of Hematology & Blood Diseases Hospital","RECRUITING","Tianjin",{"type":115,"coordinates":129},[130,131],117.17667,39.14222,{"lat":131,"lon":130},[134],{"name":94,"role":100,"phone":70,"phoneExt":70,"email":135},"Qiulg@ihcams.ac.cn",{"facility":125,"status":126,"city":127,"state":70,"zip":70,"country":112,"countryCode":113,"cosmosGeoPoint":137,"geoPoint":139,"contacts":140},{"type":115,"coordinates":138},[130,131],{"lat":131,"lon":130},[141],{"name":142,"role":100,"phone":70,"phoneExt":70,"email":143},"Gang An, MD","angang@ihcams.ac.cn",{"facility":145,"status":126,"city":146,"state":70,"zip":70,"country":112,"countryCode":113,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Wuhan Union Hospital","Wuhan",{"type":115,"coordinates":148},[149,150],114.26667,30.58333,{"lat":150,"lon":149},[153],{"name":154,"role":100,"phone":70,"phoneExt":70,"email":155},"Heng Mei, MD","mayheng@126.com",{"type":157,"investigatorFullName":70,"investigatorTitle":70,"investigatorAffiliation":70,"oldNameTitle":70,"oldOrganization":70},"SPONSOR",[159],{"name":95,"class":160},"OTHER","100600636",false,"NCT07100067","LCAR-F33S in Treatment of Relapsed\u002FRefractory Multiple Myeloma","A Clinical Study to Evaluate the Safety, Tolerance and Efficacy of LCAR- F33S Cell Therapy in Patients With Relapsed\u002FRefractory Multiple Myeloma.","Inclusion Criteria:\n\n* Subjects voluntarily participate in clinical research.\n* Age ≥18 years old.\n* Eastern Cooperative Oncology Group (ECOG) score 0-2.\n* Examination evidence of initial diagnosis of MM according to IMWG diagnostic criteria.\n* Measurable lesions were present.\n* Subjects have received treatment with one PI, one IMiD and a CD38 monoclonal antibody.\n* Subjects have received at least three previous lines of multiple myeloma therapy, each with at least one complete therapy cycle, unless the best response to the therapeutic regimen was documented as disease progression (PD confirmed according to IMWG criteria).\n* Expected survival ≥3 months.\n* Clinical laboratory values in the screening period meet criteria.\n\nExclusion Criteria:\n\n* Received previous therapy targeting FcRH5 targets.\n* Prior antineoplastic therapy and meet exclusion criteria (before apheresis);\n* Subjects had Plasma cell leukemia, Waldenstrom macroglobulinemia, POEMS syndrome, or primary AL amyloidosis at the time of screening.\n* Subjects who were positive for any of HBsAg, HBV DNA, HCV-Ab, HCV RNA, and HIV-Ab;\n* Life-threatening allergic reactions, hypersensitivity reactions, or intolerance to CAR-T cell formulations or their excipients, including DMSO, are known.\n* Serious underlying diseases were present.\n* Female subjects who were pregnant, breastfeeding, or planning to become pregnant while participating in this study or within 1 year of receiving study treatment.\n* Also enrolled in other clinical studies.","ALL","18 Years",{"count":170,"type":171},35,"ESTIMATED","INTERVENTIONAL",[72],"A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-F33S in patients with relapsed\u002Frefractory multiple myeloma(Investigator-initiated Study).",[176],"Relapsed\u002FRefractory Multiple Myeloma(MM)",[178,179],"multiple myeloma","Relapsed\u002FRefractory multiple myeloma","2025-12-25",{"date":182,"type":183},"2025-12-29","ACTUAL",{"date":185,"type":183},"2025-09-16",{"date":187,"type":171},"2029-11-20",{"name":5,"class":6},4]